| Name | Title | Contact Details |
|---|
Founded in 1904, the Fédération Internationale de Football Association (FIFA) is the umbrella organisation of its members, currently 211 national football associations. Its main objectives, enshrined in its statutes, are to develop football around the world, to stage international competitions and to protect the integrity of football (against match manipulation, doping etc.). FIFA is composed of a number of political bodies (such as the FIFA Congress and the FIFA Council) and the administration. The highest political position is the FIFA President, elected every four years by FIFAs member associations. The FIFA administration, with more than 800 people from over 60 nations, is based in Zurich. It is run by the Secretary General (CEO). FIFA stages FIFA World Cups™ in various forms such as youth, mens and womens, futsal, beach soccer or club competitions. The mens FIFA World Cup™ is not only the most popular single sporting event in the world but also the financial backbone for FIFA and its efforts to develop football worldwide. The financial success of the FIFA World Cup™ allows FIFA to run a wide range of football development programmes and to provide funds, infrastructure and know-how to its member associations through the FIFA Forward Development Programme. For more information visit our website.
Icreon is a leading customer experience transformation company providing organizations with digital strategy consulting, design, and engineering services at scale. Founded in 2000 and headquartered in New York with offices in London and New Delhi, Icreon specializes in serving Fortune 500 clients including industry leaders like Johnson Controls, Acrisure, Jets.com to the Major League Baseball Players Association. Fortune 500 companies, growing brands, and non-profits partner with Icreon to enable their next phase of growth through digital.
AIA Singapore is part of the AIA Group, which is the largest independent publicly listed pan-Asian life insurance group in the world and the second largest life insurance company in the world by market capitalisation. As a leading company in Singapore, AIA Singapore takes a leadership role in contributing to the nations social and economic progress by enabling families to live healthier, longer, better lives. Together with one of Singapores biggest and most committed team of AIA Financial Services Consultants, our dedicated staff are united in continually pursuing this goal. With a focus on providing excellent service to our customers, we partner with individuals, families and corporates in Singapore for a brighter and more prosperous future for all. Committed to the vision of being the pre-eminent life insurer in the country, admired for excellent service and best practices, AIA Singapore conducts our business according to an operating philosophy of "Doing the Right Thing, in the Right Way, with the Right People." Any personal information supplied by you in connection with your use of this social media platform may be collected, stored, handled, used and deleted in accordance with the AIA Singapore Privacy Policy available at http://www.aia.com.sg/en/index/personal-data-policy.html
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
LTCG is a leading provider of business process outsourcing for the insurance industry. The nations largest insurers rely on our unparalleled expertise to help manage their complex long-term care portfolios and maximize financial performance. We also provide clients with advanced risk management insight built upon our unique and proprietary long-term care underwriting and claims databases. LTCG has more than 1.4 million long-term care policies currently under its management, representing nearly 20% of all active policies. We serve over 50 national carriers, including every one of the top 10 insurers in the long-term care market. Our experienced management team, which has worked together for years, includes some of the most recognized and respected leaders in the long-term care industry. And our information systems have been developed specifically to support the intricacies of this unique market. To learn more, visit www.ltcg.com